Meproscillarin is a semisynthetic glycoside for the therapy of cardiac insufficiency. Meproscillarin is a drug with a high bioavailability (about 70%). Meproscillarin is at the only non-renal eliminated, lipophilic and short half-life digitalis and is therefore an ideal, cardiac inotropic agent for use in renal insufficiency. Meproscillarin can be used therapeutically in patients with liver cirrhosis, because a toxic accumulation is not to be expected. The rate of side effects of meproscillarin corresponded to that of other cardiac glycosides.

Mefeserpine (Methoxyphenoserpine) is a hypotensive reserpoid with a weak central depressive effect.

Droprenilamine hydrochloride is coronary vasodilator. It is a secondary amine structurally related to the antianginal drug prenylamine. It increases coronary flow in the isolated guinea-pig heart and partially inhibits pitressin-induced ST-segment changes in anaesthetized rats. Droprenilamine hydrochloride also elevated coronary blood flow in the anaesthetized greyhound and reduced the incidence of cardiac dysrhythmias, which result from acute ligation of the anterior descending branch of the left coronary artery. Droprenilamine hydrochloride only reduced heart rate when administered after coronary artery occlusion, a fact, which may be related to the effects of the drug on the increased sympatho-adrenal outflow produced by myocardial ischemia.

Butalamine hydrochloride under the brand name Adrevil forte is an effective drug for the treatment of patients suffering from blood flow disorders of the lower extremities.

Buquineran (UK14275), an inotropic compound, is a coronary vasolidator agent. It has been shown to exert a powerful inotropic effect with minimal effect on heart rate in dogs. Buquineran is a phosphodiesterase inhibitor. It acted as potent inhibitor of cyclic AMP hydrolysis catalysed by both PDE-II and PDE-III enzymes.

Imidapril (Tanatril), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP). In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. Some evidence suggests that imidapril also improves exercise capacity in patients with chronic heart failure (CHF) and reduces urinary albumin excretion rate in patients with type 1 diabetes mellitus. Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension.

Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.

Cilazapril (Vascace and Dynorm are brand names in a number of European countries) is an angiotensin converting enzyme (ACE; kininase II) inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Cilazapril is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. The half-life (30–50 hours) of cilazapril allows for once daily dosing unless the hypertension is severe. Cilazapril is used for the treatment of hypertension, congestive heart failure, post-myocardial infarction, and some other indications. Adverse events were mostly observed within the first 8-16 weeks of treatment, with headache, dizziness, fatigue, nausea, cough and chest pain being the most frequent.

Buterizine was developed by Janssen Pharmaceutical as a peripheral vasodilator

Zabicipril is an ethyl ester prodrug that is converted in vivo to zabiciprilat. Zabicipril induced an early, potent, and long-lasting converting enzyme inhibition. Furthermore, zabicipril did not affect plasma catecholamines and atrial natriuretic factor. It is antihypertensive and peripheral vasodilator. In normal men, zabicipril increases the renal fraction of cardiac output in the absence of a concomitant change in systemic haemodynamics. This specific effect of zabicipril on the kidney may be less important with advancing age.